Evaluation of the Safety and Effectiveness of Intradermal Administration of QR678 Neo Hair Growth Factor Formulation: A Phase-IV, Open-Label, Single-Arm Multi-Ethnicity Clinical Trial

The study evaluated the effectiveness and safety of QR678 Neo® hair re-growth factor formulation in treating androgenetic alopecia and female pattern hair loss. The open-label, prospective, and interventional study involved 2428 patients aged 18–65 years from multiple centers in different countries. The results showed that only 12% of the patients had a positive hair pull test after eight sessions. Significant improvements were observed in the global assessment score, terminal hair count, vellus hair count, and hair density after the eighth sessions. The self-assessment score also indicated high patient satisfaction. No side effects were reported during the long-term follow-up. The study concluded that intradermal administration of QR678 Neo® is an effective and safe treatment for androgenetic alopecia and female pattern hair loss.